总的来说,lutetium Lu 177 vipivotide tetraxetan通过与亮点素受体结合并释放高能射线,能够正确地杀死肿瘤细胞,从而达 lutetium Lu 177 vipivotide tetraxetan (Pluvicto)的靶基因在 prostate cancer的发生与恶化、转移中的作用 lutetium Lu 177 vipivotide tetraxetan (Pluvicto)是一种用于治疗前列腺癌的放射性药物。...
[摘要] 镥-177标记前列腺特异性膜抗原放射性配体疗法(177Lu-labeled prostate-specific membrane antigen radioligand therapy,177Lu-PSMA-RLT)是一种通过精准地向前列腺癌细胞递送177Lu释放的β射线,引发肿瘤细胞DNA的辐射损伤从而杀灭肿瘤的...
1.Baum RP, Kulkarni HR, Schuchardt C, et al. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. J Nucl Med. 2016 Jul;57(7):1006-13. 2.Schuchar...
177Lu-PSMA RPT:流程和动力学 前列腺特异性膜抗原(PSMA)在前列腺癌中高表达。美国FDA批准的三种PSMA显像化合物——68Ga -PSMA-11,18F-DCFPyL和18F-flotufolastat (Posluma;Blue Earth Diagnostics) -确定177Lu-PSMA治疗的资格,而对于RPT,177Lu-PSMA-617和177Lu-PSMA-I&T是可用的,尽管后者仍处于临床试验阶段。
Evidence-based Medicine. The purpose of this consensus was to provide physicians with reference for clinical application in the practice of 177Lu-PSMA-RLT for the treatment of prostate cancer based on existing evidence and lay the foundation for the development of subsequent industry-related ...
(177)Lu-PSMA Radioligand therapy for prostate cancer. J Nucl Med. (2017) 58:1196-200. doi: 10.2967/jnumed.117.191023Fendler WP, Rahbar K, Herrmann K, Kratochwil C, Eiber M. (177)Lu-PSMA Radioligand Therapy for Prostate Cancer. J Nucl Med 2017;58(8):1196-200....
Lu-177-PSMA Radioligand Therapy for Prostate Cancer (vol 58, pg 1196, 2017) Fendler - 《Journal of Nuclear Medicine》 被引量: 0发表: 2018年 (177)Lu-PSMA radioligand therapy for prostate cancer Lu-177-prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) using inhibitors of ...
Radioligand therapy with 177Lu-Prostate specific membrane antigen (PSMA) is an innovative and effective therapy for patients with castration-resistant metastatic prostate cancer. PSMA is expected to be a standard regimen for prostate cancer as it is well tolerated by patients and has high potential ...
[177lu] lu-psma-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (therap): a randomised, open-label, phase 2 trial lancet, 397 (10276) (2021), pp. 797-804 view in scopus google scholar 11 p.s. choudhury, m. gupta precision oncology through radiating ...
, 西南医科大学附属医院核医学科,核医学与分子影像四川省重点实验室,泸州 646000 基金项目: 泸州市-西南医科大学核素精准诊疗研究项目(2016lzxnyd-g01) 详细信息 progress in radioligand therapy with 177 lu-psma for the treatment of metastatic castration-resistant prostate cancer yanhong zhao , yue chen , ...